 Apnimed, Inc.  
[ADDRESS_1119601]  
Cambridge, MA  [ZIP_CODE]  
[EMAIL_4003]  
 
Page 1 of 1 
CONFIDENTIAL. DO NOT  DISTRIBUTE WITHOUT PERMISSION.  
 
October 18 , 2022  
 
To: Clin icalT rials.gov  
 
This is a cover page to the redacted clinical protocol  for APC -003 titled  Phase 2 Double -
Blind Placebo -Controlled 4-Period Single -Dose Crossover  Factorial  Study to Evaluate  the 
Contribution of the Individual Drug Components to the Efficacy of the Combination of 
Atomoxetine and R -oxybutynin in Obstructive Sleep Apnea . 
 
The APC -003 clinical protocol  is associated with [STUDY_ID_REMOVED] .   
 
The following proprietary information was redacted from the clinical protocol  for APC -003:  
 IND number  
 
Sincerely,  
 
 
 
 
 
Jeanne Brittain  
Director, Program Management  
 
 
Quality Approval:   
Name  [CONTACT_203798] , GXP 
Quality Assurance   
 
 
 
 
 
  
 
10/19/2022

Apnimed, Inc.   Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January  2021 1 of 50 V2.0 Title Page  
Protocol Title : Phase 2 Randomized Double- Blind Placebo -Controlled 4-Period Single- Dose 
Crossover Factorial Study to Evaluate the Contribution of the Individual Drug Components to 
the Efficacy of the Combination of Atomoxetine and R-oxybutynin in Obstructive Sleep Apnea 
Protocol Number: AP C-003 
Version Number: 2.0 
Compound Number:  AD109 
Short Title:  AD109 Factorial Study 
Sponsor Name [CONTACT_29560]:   
Apnimed, Inc. 
[ADDRESS_1119602] Cambridge, MA [ZIP_CODE] Regulatory Agency Identifying Number:  IND 141505 
Approval Date : 6 January  2021 
Date and Version of Previous Protocol:  6 October  2020, Version 1.3  
 
  
Apnimed. Inc.
Protocol APC-0O3ilND 141505
Sponsor Signatory:Clinical Study Protocol
CONF'IDENTIAL
li )^1 LcLl
Date
6 January 2021 2 of50 v2.0
Apnimed, Inc.   Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January  2021 3 of 50 V2.0 Table of Contents  
 
Table of Contents ............................................................................................................................ 3  
1 Protocol Summary .................................................................................................................... 6  
1.1 Synopsis ................................................................................................................................ 6  
1.2 Schedule of Activities (SoA) ................................................................................................ 8  
2 Introduction............................................................................................................................... 9  
2.1 Study Rationale .................................................................................................................... 9  
2.2 Background ........................................................................................................................... 9  
2.2.1  Obstructive Sleep  Apnea .................................................................................................. 9  
2.2.2  Unmet Medical  Need  ...................................................................................................... 10  
2.2.3  Biological Rationale  ....................................................................................................... 10  
3 Endpoints .................................................................................................................................11  
4 Study Design ............................................................................................................................11  
4.1 Overall Design  .....................................................................................................................11  
4.2 Scientific Rationale for Study Design and Dose ................................................................ 13  
4.3 End of Study Definition...................................................................................................... 13  
5 Study Population ..................................................................................................................... 13  
5.1 Inclusion Criteria  ................................................................................................................ 13  
5.2 Exclus ion Criteria  ............................................................................................................... 15  
5.3 Meals and Dietary Restrictions  .......................................................................................... 17  
5.4 Caffeine, Alcohol, and Tobacco .......................................................................................... 17  
5.5 Activity  ............................................................................................................................... 17  
5.6 Screen Failures  ................................................................................................................... 17  
6 Study Treatment  ...................................................................................................................... 18  
6.1 Study Treatm ent(s) Administered  ....................................................................................... 18  
6.2 Preparation/Handling/Storage/Accountability ................................................................... 18  
6.3 Measures to Minimize Bias: Randomization and Blinding  ................................................ 19  
6.4 Concomitant Therapy  ......................................................................................................... 19  
6.5 Discontinuation of Study Treatment ................................................................................... 22  
6.6 Stoppi[INVESTIGATOR_2121] ................................................................................................................ 22  
Apnimed, Inc.   Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January  2021 4 of 50 V2.0 6.6.1  Individual Participant Stoppi[INVESTIGATOR_2121] ......................................................................... 22  
6.7 Participant Discontinuation/Withdrawal from the Study ................................................... 22  
6.8 Loss of Participants to Follow- Up ...................................................................................... 23  
7 Study Assessments and Procedures ........................................................................................ 23  
7.1.1  Polysomnography ........................................................................................................... 24  
7.2 Safety Assessments  ............................................................................................................. 24  
7.2.1  Physical Examinations .................................................................................................... 25  
7.2.2  Vital Signs  ...................................................................................................................... 25  
7.2.3  Electrocardiograms  ......................................................................................................... 25  
7.2.4  Clinical Safety Laboratory Assessments  ........................................................................ 25  
7.3 Adverse Events and Serious Adverse Events ..................................................................... 26  
7.3.1  Time Period and Frequency for Collecting AE and SAE Information ........................... 26  
7.3.2  Method of Detecting AEs and SAEs .............................................................................. 26  
7.3.3  Follow-up of AEs and SAEs ........................................................................................... 27  
7.3.4  Regulatory Reporting Requirements for SAEs .............................................................. 27  
7.3.5  Pregnancy  ....................................................................................................................... 27  
7.4 Treatment of Overdose ....................................................................................................... 28  
7.5 Pharmacokinetics  ................................................................................................................ 28  
8 Statistical Considerations ........................................................................................................ 28  
8.1 Sample Size Determination  ................................................................................................ 28  
8.2 Populations for Analyses  .................................................................................................... 28  
8.3 Interim Analyses  ................................................................................................................. 29  
9 Supporting Documentation and Operational Considerations ................................................. 29  
9.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ............................ 29  
9.1.1  Regulatory and Ethical Considerations .......................................................................... 29  
9.1.2  Financial Disclosure  ....................................................................................................... 30  
9.1.3  Informed Consent Process .............................................................................................. 30  
9.1.4  Data Protection  ............................................................................................................... 31  
9.1.5  Data Quality Assurance  .................................................................................................. 31  
9.1.6  Source Documents .......................................................................................................... 32  
9.1.7  Study and Site Closure ................................................................................................... 33  
9.1.8  Publication Policy  ........................................................................................................... 33  
9.1.9  Protocol Approval and Amendment  ............................................................................... 33  
9.1.10  Liability and Insurance ................................................................................................... 34  
9.2 Appendix 2: Clinical Laboratory Tests  ............................................................................... 35  
Apnimed, Inc.   Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January  2021 5 of 50 V2.0 9.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting ................................................................................................... 36  
9.4 Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information .............. 43  
9.5 Appendix 5: List of Abbreviations ..................................................................................... 47  
10 References ............................................................................................................................... 49  
 
Apnimed, Inc.   Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January  2021 6 of 50 V2.0 1 Protocol Summary 
1.1 Synopsis  
Protocol Title:  Phase 2 Randomized Double- Blind Placebo -Controlled 4-Period Single- Dose 
Crossover Factorial Study to Evaluate the Contribution of the Individual Drug Components to 
the Efficacy of the Combination of Atomoxetine and R-oxybutynin in Obstructive Sleep Apnea 
Sponsor Study No.: AP C-003 
Phase : 2 
Sponsor:  Apnimed, Inc. 
Rationale: 
Previous studies conducted by [CONTACT_456] (under IND 136752) and academic investigators 
indicate that the combination drug composed of atomoxetine and oxybutynin (designated 
AD036) is effective for the treatment of obstructive sleep apnea (OSA) . Oxybutynin is a racemic 
mixture of R and S enantiomers. Oxybutynin is approved in the U.S. for overactive bladder. Efficacy  of oxybutynin in overactive bladder may result b oth from antimuscarinic effects and 
smooth muscle spasmolytic effects. The contribution to efficacy of oxybutynin in OSA is 
believed to be related to  the antimuscarinic effects, whereas spasmolytic effects may lead to 
effects on the bladder that are undesirable in typi[INVESTIGATOR_809619]. The R-enantiomer of 
oxybutynin has been shown to confer the antimuscarinic effect of oxybutynin, whereas the spasmolytic effects (and other effects on calcium channel antagonism and local anesthetic 
effects) are non -stereosel ective properties of both the enantiomers.  Apnimed therefore believes 
that the combination of the R-enantiomer of oxybutynin with atomoxetine, designated AD109, 
may have an improved safety and efficacy profile in OSA compared to the combination with the racemate of oxybutynin.  
This factorial study is designed to demonstrate that both atomoxetine and R-oxybutynin 
contribute to the efficacy of AD109 in OSA, and thus to fulfill FDA requirements for approval of combination drugs under 21 CFR Subpart B Section 300.50 Fixed-combination prescription drugs for humans. 
 
Apnimed, Inc.   Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January  2021 7 of 50 V2.0 Overall Design : 
Study AP C-003 is a randomized, double blind, placebo-controlled, 4-period, single-dose 
crossover factorial study in patients with OSA . A screening visit and polysomnographic  (PSG) 
exam will be conducted to establish that each participant meets study enrollment criteria . Each 
participant will then  receive a single dose of each of the following during 4 overnight PSG 
exams , each separated by a one week washout period: 
• Atomoxetine 75 mg + R -oxybutynin 2.5 mg (AD109) 
• Atomoxetine 75 mg  
• R-oxybutynin 2.5 mg 
• Placebo  
The primary hypothesis of the crossover study is that AD109  is superior to each of the other 3 
arms , on the endpoint of Hypoxic Burden (HB), a measure of the depth and duration of the 
ventilatory disturbance in  OSA.  
Number of Participant s: 
A total of 58 participants will be  enrolled . 
Study Duration: 
The overall study duration will be  up to 14 weeks, as follows:  
• Screening , up to 4 weeks; 
• 4-period crossover, up to 8 weeks ; 
• End of Study Evaluation, [ADDRESS_1119603] crossover period 
Apnimed, Inc.   Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January  2021 8 of 50 V2.0 1.2 Schedule of Activities  (SoA)   
Table [ADDRESS_1119604] Crossover Period Visit 3-6 End of Study Evaluation1 
Daytime  
V1 PSG  
V2 PSG  
V3 Wash -
out 2 PSG  
V4 Wash -
out PSG  
V5 Wash -
out PSG  
V6 Wash -
out  
Trial Da y (Visit Window)  Up to [ADDRESS_1119605] V6 ± [ADDRESS_1119606]  X           
Pregnancy test3 X           
12 Lead ECG  X           
PSG Exam   X4 X  X  X  X   
Randomization5   X         
Administration of study treatment6    X  X  X  X   
DSST7   X  X  X  X   
Vital signs8 X X X  X  X  X   
AE/SAE monitoring    X X X X X X X X X 
Prior/concomitant medication monitoring  X X X X X X X X X X X 
Abbreviations: AE = adverse event; DSST = Digit Symbol Substitution Test; ECG = electrocardiogram; ESS = Epworth Sleepi[INVESTIGATOR_008] S cale; PSG = polysomnography; SAE = serious 
adverse event; WOCBP  = women of childbearing potential.  
 
[ADDRESS_1119607] crossover period  
6 Study medication administered immediately before lights out 
7 Administer at similar time after awakening after each crossover PSG, approximately 1 hour after awakening  
8 Vital signs include the following: seated blood pressure, pulse, respi[INVESTIGATOR_697]; vital signs on PSG nights taken after admission to PSG lab  
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 9 of 50 V2.0 2 Introduction  
2.1 Study Rationale  
Previous studies conducted by [CONTACT_456] (under IND 136752) and academic investigators 
indicate that the combin ation drug composed of atomoxetine and oxybutynin (designated 
AD036) is effective for the treatment of obstructive sleep apnea (OSA). Oxybutynin is a racemic mixture of R and S enantiomers. Oxybutynin is approved in the U.S. for overactive bladder. 
Efficac y in overactive bladder may result both from antimuscarinic effects of oxybutynin and 
smooth muscle spasmolytic effects. The contribution to efficacy of oxybutynin in OSA is 
believed to be related to antimuscarinic effects, whereas spasmolytic effects may lead to effects on the bladder that are undesirable in typi[INVESTIGATOR_809619]. The R-enantiomer of oxybutynin has 
been shown to confer the antimuscarinic effect of oxybutynin, whereas the spasmolytic effects 
(and other effects on calcium channel antagonism a nd local anesthetic effects) are non -
stereoselective properties of both the enantiomers.  Apnimed therefore believes that the 
combination of the R-enantiomer of oxybutynin with atomoxetine, designated AD109, may have 
an improved safety and efficacy profile in OSA compared to the combination with the racemate of oxybutynin.  
This factorial study is designed to demonstrate that both atomoxetine and R-oxybutynin 
contribute to the efficacy of AD109 in OSA, and thus to fulfill FDA requirements for approval of 
combination drugs under [ADDRESS_1119608] common and serious of these sleep disorders and affects 
approximately 20 million people in the [LOCATION_002] ( US), with approximately 13% of men and 
6% of women affected  (Peppard et al, 2013) . OSA is characterized  by [CONTACT_203781] 
‘obstruction’ of the pharyngeal airway during sleep, manifesting as repetitive epi[INVESTIGATOR_203751] (i.e., shallow breathing) or apnea (i.e., paused breathing). These epi[INVESTIGATOR_203752],  sleep fragmentation , excessive daytime sleepi[INVESTIGATOR_008], 
and/or neuropsychological impairment.  
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 10 of 50 V2.0 Research has shown that a number of pathogenic factors, or traits, contribute to the development 
of OSA  (Eckert et al, 2013; Wellman et al, 2011 ; Wellman et al, 2013;Younes, 2003). The most 
important factors are the presence of  an anatomically small, collapsible upper airway and a loss 
of pharyngeal muscle tone or responsiveness during sleep.  
Long-term, OSA is associated with increased mortality and a number of adverse cardiovascular , 
neurocognitive, metabolic, and daytime functioning consequences (Somers et al, 1995 ; Nieto et al, 
2000; Brooks et al, 1997; Peppard et al, 2000; Hung et al, 1990; Wessendorf et al, 2000; Hoffstein, 1994;  
Shahar et al, 2001 ; Redline et al, 1997; Findley e t al, 1988) . 
2.2.[ADDRESS_1119609] pressure (CPAP), provided by a machine that  mechanically maintains an open airway. 
Other treatments, such as pharyngeal surgery, mandibular advancement devices, and implantable nerve stimulators, were developed to address the anatomical predisposition to collapse; however, 
they have shown limited efficacy for niche populations. 
While CPAP and related therapi[INVESTIGATOR_809620], many, perhaps most, patients find these devices uncomfortable or intolerable, and 
most estimates indicate that fewer than 50% of patients prescribed  CPAP  use it more than 4 hours 
per night, if at all (Weaver and Sawyer, 2010). Efforts to develop pharmacologic therapi[INVESTIGATOR_014], such 
as antidepressants, stimulants, and hormonal agents, for the treatment of OSA have been ongoing 
for at least 20 years, with no success thus far. 
As many patients cannot use CPAP because they find it int olerable, this represents  a significant 
health concern, as OSA is associated with numerous co- morbidities  and increased mortality. 
Alternative options, such as drugs that activate the pharyngeal muscles, are needed.  
2.2.3 Biological Rationale  
AD109 is a new fixed dose drug combination of atomoxetine and R-oxybutynin being developed 
for OSA. Atomoxetine is a pre -synaptic norepi[INVESTIGATOR_633483]. R-oxybutynin has never 
been marketed, but racemic o xybutynin is  approved as  an antispasmodic drug that inhibits the 
muscarinic action of acetylcholine on smooth muscle and is indicated for the treatment of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic 
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND [ADDRESS_1119610] of oxybutynin, whereas the spasmolytic effects (and other effects on calcium channel antagonism and local anesthetic effects) are non -stereoselective properties of both the enantiom ers.  Apnimed therefore believes that the 
combination of the R -enantiomer of oxybutynin with atomoxetine may have an improved safety 
and efficacy profile in OSA compared to the combination with the racemate of oxybutynin. This factorial study, APC -003, is designed to demonstrate that both atomoxetine and R -oxybutynin 
contribute to the efficacy of AD109 in OSA.  
3 Endpoints  
4 Study Design  
4.1 Overall Design  
Study APC -003 is a double-blind, placebo-controlled 4-period single dose crossover study 
designed to demonstrate the individual contribution of atomoxetine and R-oxybutynin to the efficacy of AD109.   Endpoints  
Primary  
 • Change in Hypoxic Burden (HB)  4%, (scored in reference to AHI 4%), AD109 
vs. other 3 study treatments  
  Secondary   • Change in Apnea Hypopnea Index (AHI)  4% 
• Change in Oxygen Desaturation Index (ODI)  
• Total time with SaO 2 <90%, PSG nights  
• Proportion of participants with ≥50% reduction, AHI, HB and ODI  
Exploratory • PSG s leep and arousal parameters  
• PSG respi[INVESTIGATOR_809621]  • Physical exam, vital signs, clinical laboratory assessment  
• Spontaneous adverse events, including the post -dosing period 
• DSST  
• PSG parameters: heart rate, ECG, EEG, oximetry  
Abbreviations: AHI = apnea -hypopnea index ; DSST = Digit Symbol Substitution Test;  ECG = electrocardiogram; 
EEG = electroencephalogram;  HB = Hypoxic Burden; ODI = Oxygen Desaturation Index;  OSA = obstructive 
sleep apnea; PSG = polysomnography; SaO 2 = oxygen saturation.  
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND [ADDRESS_1119611] a previous history of OSA of a severity 
consistent with enrollment criteria or be at high risk (e.g. as assessed by [CONTACT_617386]-Bang 
Questionnaire score).  Only patients who meet all non- PSG enrollment criteria at Visit [ADDRESS_1119612] of a screening PSG.  
Patients  who meet all enrollment crite ria will be randomized  to receive the following 
experimental treatments , one treatment  on each of 4 PSG night: 
• Atomoxetine 75 mg + R-oxybutynin 2.5 mg (AD109) 
• Atomoxetine 75 mg 
• R-oxybutynin 2.5 mg 
• Placebo  
Dosing of the study treatment will occur immediately prior to lights out. Each morning following 
PSG exams in the crossover period the DSST will be administered.  
Each PSG night is followed by a 1-week washout period. AE/SAE information is recorded at 
each study visit and by [CONTACT_809625]. Overall study duration will be up to 14 weeks. A total of 58 
participants will be enrolled. Participants who withdraw from the study will not be replaced.  
Figure 1: Overview of Study Design 
 
 
PSG = polysomnography.   

Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 13 of 50 V2.0  
4.2 Scientific Rationale for Study Design  and Dose  
Previous Phase 2 studies conducted by [CONTACT_809626], and that both drug 
components are necessary for this efficacy. This factorial study is designe d to demonstrate that 
both atomoxetine and R-oxybutynin contribute to the efficacy of AD109 in OSA. The dose of 
atomoxetine has been used in previous Phase 2 studies supporting efficacy and safety for OSA in 
combination with 5 mg racemic oxybutynin. Becaus e the R -enantiomer of oxybutynin confers 
about 2-fold the anticholinergic activity of the racemate, with such activity thought to be the 
major contributor to efficacy in OSA, the dose of R-oxybutynin was reduced to 2.5 mg. 
A detailed description of the chemistry, pharmacology, efficacy, and safety of AD109 is 
provided in the Investigator’s Brochure. 
4.[ADDRESS_1119613] completed the study if he/she has completed all phases of the 
study through the last scheduled procedure shown in the Schedule of Activities (SoA). 
The end of the study is defined as the date of the last visit of the last participant in the study or last 
scheduled procedure shown in the SoA for the last participant in the study globally. 
 
[ADDRESS_1119614] be able to provide written consent and meet all the inclusion criteria and none 
of the exclusion criteria. 
5.1 Inclusion Criteria  
Age and Sex  
1. Between 25 to 65 years of age, inclusive, at the Screening Visit. 
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 14 of 50 V2.0 Objective Disease Measures  
2. AHI 10 to <45, or AHI ≥45 if any one of the following criteria are met:  
a. Fraction of hypopneas (F hypopnea ) is >90% or 
b. Mean oxygen desaturation of obstructive events is ≤4% or 
c. Fraction of hypopneas is 50-90% and  mean oxygen desaturation is 4- 8%  
Note: Hypopneas defined by 4% oxygen desaturation  
Weight  
3. BMI between 18.5 and 40.0 kg/m2, inclusive, at the pre- PSG visit.  
Male participants:  
4. If male and sexually active with female partner(s) of childbearing potential, participant  
must agree, from Study Day [ADDRESS_1119615] do se of study drug, to 
practice the protocol specified contraception  (see Appendix 4: Contraceptive Guidance 
and Collection of Pregnancy Information). 
Female participants:  
5. If a woman of childbearing potential ( WOCBP ), the participant  must agree , from Study 
Day [ADDRESS_1119616] dose of study drug, to practice the protocol specified 
contraception (See Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information). All WOCBP  must have negative result of a serum pregnancy test performed 
at screening .  
6. If female and of non-childbearing potential, the participant must be either postmenopausal (defined as age ≥ 55 years with no menses for 12 or more months without an alternative medical cause) or permanently surgically sterile (bilateral 
oophorectomy, bilateral salpi[INVESTIGATOR_49838]).  
Informed Consent  
7. Participant  voluntarily agrees to participate in this study and signs an Institutional Review 
Board (IRB)-approved informed consent prior to performing any of the Screening Visit procedures. 
8. Participa nt must be able to understand the nature of the study and must have the 
opportunity to have any questions answered. 
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 15 of 50 V2.0 5.2 Exclusion Criteria  
Participant s are excluded from the study if any of the following criteria apply: 
Medical Conditions  
1. History of narcolepsy. 
2. Clinically significant craniofacial malformation.  
3. Clinically significant cardiac disease (e.g., rhythm disturbances, coronary artery disease or 
cardiac failure) or hypertension requiring more than 2 medications for control  (combination 
medications count as 1 medication) .  
4. Clinically significant neurological disorder, including epi[INVESTIGATOR_002]/convulsions. 
5. History of schizophrenia, schizoaffective disorder or bipolar disorder according to Diagnostic and Statistical Manual of Mental Disorders -5 (DSM -5) or International 
Classification of Disease tenth edition  criteria . 
6. History of attempted suicide or suicidal ideation within 1 year prior to screening, or current 
suicidal ideation . 
7. History of clinically significant constipation, gastric retention, urinary retention or insomnia. 
8. Medically unexplained positive screen for drugs of abuse (excluding THC/marijuana) or 
history of substance use disorder as defined in DSM -V within [ADDRESS_1119617] 30 days  as 
determined by [CONTACT_1697]. 
10. Clinically significant cognitive dysfunction as determined by [CONTACT_1697]. 
11. Untreated narrow angle glaucoma.  
12. Women who are pregnant or nursing. 
Prior/Concomitant Therapy  
13. CPAP should not be used for at least [ADDRESS_1119618] study PSG  and throughout the 
study. 
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND [ADDRESS_1119619] of disallowed concomitant medications.  
18. Treatment with strong cytochrome P450 3A4 ( CYP3A4 ) inhibitors, strong 
cytochrome P450 2D6 ( CYP2D6 ) inhibitors, or monoamine oxidase inhibitors (MAOI) 
within 14 days of the start of treatment, or concomitant with treatment.  
Prior/Concurrent Clinical Study  Experience 
19. Use of another investigational agent within 30 days or 5 half -lives, whichever is longer, 
prior to dosing.  
Diagnostic Assessments  
20. ESS total score > 18 . 
21. Hepatic transaminases > 2X the upper limit of normal ( ULN) , total bilirubin > 1.5X ULN 
(unless confirmed Gilbert syndrome), estimated glomerular filtration rate  < 60 ml/min .  
Other Exclusions  
22. <[ADDRESS_1119620]  units/day for men or 1 units/day for women, not to be consumed within 3 hours 
of bedtime. 
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 17 of 50 V2.0 28. Unwilling to limit during the study period caffeinated beverage intake (e.g., coffee, cola, 
tea) to 400 mg/day or less of caffeine, not to be used within 3 hours of bedtime. 
29. Any condition that in the investigator’s opi[INVESTIGATOR_203760] , or which would interfere with their participation in the study or confound study 
interpretation . 
30. Participant  considered by [CONTACT_093], for any reason, an unsuitable candidate to 
receive AD109 or unable or unlikely to understand or comply with the dosing schedule or 
study evaluations. 
5.3 Meals and Dietary Restrictions 
1. Participant s should refrain from consumption of any nutrients known to modulate CYP 
enzyme activity (e.g., grapefruit or grapefruit juice, pomelo juice, star fruit, pomegranate, 
and Seville or Moro [blood] orange products) within [ADDRESS_1119621] units per day  for men or 1 unit/day for women of alcohol, consumed no less than 
3 hours prior to bedtime. Alcohol should not be consumed on PSG nights. 
2. Moderate consumption of caffeinated beverages , containing up to a total of 400 mg 
caffeine per day, is permitted  during the study period, consumed no less than 3 hours prior 
to bedtime.   
5.5 Activity 
There are no restrictions on physical activity during the study other than that physical activity 
should be generally stable during the study (e.g., new exercise programs should not be initiated). 
5.6 Screen Failu res 
Screen failures are defined as participant s who consent to participate in the clinical study but are 
not subsequently randomized  to study treatment /entered in to the study. A minimal set of screen 
failure information is required to ensure transparent reporting of screen failure participant s that 
meet s the Consolidated Standards of Reporting Trials publishing requirements and to respond to 
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 18 of 50 V2.0 queries from regulatory authorities. Minimal information includes demography, screen failure 
details, eligibility criteria, and any serious adverse events  (SAE s). 
Individuals who do not meet the criteria for participation in this study (screen failure) will not be 
rescreened , except if the opportunity for rescreening has been enabled by [CONTACT_12548]. 
6 Study Treatment  
Study treatment  is defined as an y investigational treatment (s), marketed product(s), placebo, or 
medical device (s) intended to be administered to a study participant according to the study 
protocol. 
6.1 Study Treatment (s) Administered  
Two capsules are taken each night of drug treatment , either :  
• 1 capsule of atomoxetine 75 mg + 1 capsule of R-oxybutynin 2.5 mg  
• 1 capsule of atomoxetine 75 mg and 1 capsule of placebo 
• 1 capsule of R-oxybutynin 2.5 mg and 1 capsule of placebo  
• 2 capsules of placebo 
 Study medication is taken immediately prior to lights out.  
Study Treatment  Name:  [CONTACT_809628]  R-Oxybutynin chloride  or 
Placebo  
Dosage Formulation:  Opaque White Capsule , 
size 1 (about 0.75” length) Opaque White Capsule , 
size 4 (about 0.5” length) 
Dosage Level:  75 mg  or placebo  2.5 mg or placebo  
Route of Administration: Oral Oral 
Dosing Instructions:  1 capsule administered 
with up to 240 mL water  1 capsule administered with up to 240 mL water  
Storage/Packaging/Labeling:  
 Store  at room temperature, 
in HDPE bottles  Store at room temperature 
in HDPE bottles  
6.2 Preparation/Handling/Storage/Accountability  
1. The Investigator or designee must maintain a log to confirm appropriate temperature 
conditions have been maintained during transit for all study treatments  received and any 
discrepancies are reported and resolved  before use of the study treatment . 
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND [ADDRESS_1119622] be stored 
in a secure, environmentally controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the Investigator and 
authorized site staff.  
3. The Investigator, institution, or the hea d of the medical institution (where applicable) is 
responsible for study treatment accountability, reconciliation, and record maintenance (i.e., receipt, reconciliation, and final disposition records). 
4. After receiving Sponsor approval in writing, sites are responsible for returning all unused or partially used study treatment to the Sponsor or designated third party or for preparing 
the study treatment  for destruction via incineration. 
6.3 Measures to Minimize Bias: Randomization and Blinding  
All participants will be centrally randomized for the crossover phase of the study. Each 
participant will be assigned a unique number (randomization number) that encodes the participant’s assignment to 1 of the sequences of the study, according to the randomization 
schedule using a validated computer program.  
Returned study treatment should not be redispensed to the participants. 
In case of an emergency, the Investigator has the sole responsibility for determining if 
unblinding of a participant’s study treatment assignment is warranted. Participant safety must always be the first consideration in making such a determination. If the Investigator decides that unblinding is warranted, the Investigator should make every effort to contact [CONTACT_416468] a participant’s study treatment assignment unless this could delay emergency 
treatment of the participant. If a participant’s study treatment assignment is unblinded, the Sponsor must be notified within [ADDRESS_1119623] be recorded in the source documentation and electronic case report form 
(eCRF), as applicable.  
In the event of a Quality Assurance audit, the auditor(s) will be allowed access to unblinded 
study treatment records at the site(s) to v erify that randomization/dispensing has been done 
accurately.  
6.4 Concomitant Therapy  
Concomitant therapy with the medication s listed below is disallowed . For medication that is 
typi[INVESTIGATOR_608914]-needed for symptomatic conditions (e.g. occasional use of a sleep aid) , the 
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND [ADDRESS_1119624] study PSG an d for the 
duration of the study.  
• MAOIs  or other drugs that affect monoamine concentrations (e.g., rasagiline) [ MAOIs  are 
contraindicated for use with atomoxetine] 
• Selective Serotonin R euptake Inhibitors (e.g., paroxetine) 
• Selective Norepi[INVESTIGATOR_75618] (e.g., duloxetine) 
• Norepi[INVESTIGATOR_75618] (e.g., reboxetine) 
• Alpha-1 antagonists (e.g., tamsulosin) 
• Tricyclic antidepressants (e.g., desipramine) 
• CYP2D6 inhibitors  
• Strong CYP3A4 inhibitors (e.g., ketoconazole) 
• Benzodiazepi[INVESTIGATOR_203761] 
• Opi[INVESTIGATOR_2438] 
• Sedatives incl uding nonbenzodiazepi[INVESTIGATOR_050] “Z-drugs” (zolpi[INVESTIGATOR_6730], zaleplon, eszopi[INVESTIGATOR_11123]) 
• Muscle relaxants  
• Pressor agents  
• Drugs with clinically significant cardiac QT-interval  prolonging effects 
• Drugs known to lower seizure threshold (e.g., chloroquine) 
• Amphetamines  
• Antiepi[INVESTIGATOR_23698]  
• Antiemetics  
• Modafinil or armodafinil 
• Beta 2 agonists, (e.g., albuterol) 
• Antip sychotics 
• Anticholinergics and anticholinesterase inhibitors, including drugs with substantial 
anticholinergic side effects, (e.g., first generation antihistamines) 
• Sedating antihistamines  
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 21 of 50 V2.0 • Pseudoephedrine, phenylephrine, oxymetazoline 
• Nicotine replacement products  
• Most drugs for Parkinson’s, Alzheimer’s, Huntington’ s, Amyotrophic L ateral Sclerosis , or 
drugs for other neurodegenerative diseases 
Medications that do not have subs tantial effects on the central nervous system ( CNS ), 
respi[INVESTIGATOR_1516], or muscle activity are generally allowed if dose and frequency is stable for 1 month 
prior to enrollment, including, but not necessarily limited to, the following drugs and drug classes:  
• Antihypertensives (angiotensin-converting- enzyme/angiotensin II receptor blocker inhibitors, 
calcium channel blockers, spi[INVESTIGATOR_8407], hydrochlorothiaz ide, etc.)  
• Statins  
• Proton pump inhibitors and histamine h
2 receptor blockers 
• Over-the-counter (O TC) antacids  
• Non-sedating antihistamines (e.g., cetirizine, loratadine) 
• Melatonin  
• Non- steroidal anti-inflammatory drugs and acetaminophen 
• Laxatives  
• Erectile dysfunction drugs 
• Inhaled corticosteroids (e.g., fluticasone) 
• Antidiabetics  
• Ocular hypotensives and other ophthalmics (e.g., timolol) 
• Hormonal therapy (e.g., estrogen replacement or anti-estrogens) and hormonal contraceptives 
• Thyroid medications 
• Anticoagulants 
• OTC topi[INVESTIGATOR_8593] (e.g., topi[INVESTIGATOR_203762]) 
• Osteoporosis drugs 
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 22 of 50 V2.0 6.5 Discontinuati on of Study Treatment  
If a clinically significant finding is identified, the Investigator or qualified designee will 
determine if the participant can continue in the study and if any change in participant 
management is needed. Any new clinically relevant f inding should be reported as an adverse 
event ( AE). 
6.6 Stoppi[INVESTIGATOR_2121]  
6.6.1 Individual Participant Stoppi[INVESTIGATOR_2121]  
• Incidents of abuse, diversion, or misuse of the study treatment.  
• Incident s of clinical  significan ce: hallucinations, amnesia, delusional thinking, delirium, 
manic symptoms, aggressive behavior, suicidality, homicidality, agitation, confusion, or convulsions/seizures. 
• Participants  report ing any SAE considered possibly related or related to study treatment. 
• Acute urinary obstruction. 
• Any other AE that in the judgment of the I nvestigator necessitates the participant  stoppi[INVESTIGATOR_618967] . 
Participants discontinued from dosing will undergo end of study procedures with follow-up monitoring of the AE(s) as clinically indicated.  
6.7 Participant Discontinuation/Withdrawal from the Study  
• A participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the Investigator for safety, behavioral, or 
admin istrative reasons.  
• If the participant withdraws consent for disclosure of future information, the Sponsor may 
retain and continue to use any data collected before such a withdrawal of consent. 
• If a participant withdraws from the study, he/she may request destruction of any samples taken and not tested, and the Investigator must document this in the site study records. 
• All participants who withdraw from the study with an ongoing AE must be followed until the event is resolved or deemed stable.  
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 23 of 50 V2.0 • Participation may be terminated before completing the study and the reason recorded as 
follows: 
o Withdrawal due to AE 
o Withdrawal due to incident abuse, diversion, or misuse of the study treatment 
o Loss to follow-up 
o Participant withdrew consent at own request  
o Other  
6.[ADDRESS_1119625] be 
taken if a participant fails to return  to the clinic for a required study visit: 
• The site must attempt to contact [CONTACT_185610] (and within the visit window, where one is defined) and counsel the participant on 
the importance of maintaining the assigned visit schedule and ascertain whether or not the participant wishes to and/or should continue in the study. 
• In cases in which the participant is deemed lost to follow-up, the Investigator or designee 
must make every effort to regain contact [CONTACT_625889] (where possible, 3 telephone 
calls and, if necessary, a certified letter to the participant’s last known mailing address or 
local equivalent methods). These contact [CONTACT_13140]’s 
medic al record/ eCRF . 
• Should the participant continue to be unreachable, he/she will be considered to have withdrawn from the study. 
7 Study Assessments and Procedures  
• Study procedures and their timing are summarized in the SoA. 
• Adherence to the study design requirements, including those specified in the SoA, is essential and required for study conduct. 
• All screening evaluations must be completed and reviewed to confirm that potential participants meet all eligibility criteria. The Investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for screening failure, as applicable.  
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 24 of 50 V2.0 • The maximum amount of blood collected from each participant over the duration of the 
study, excluding any extra assessments that may be required  for safety or technical issues, 
will not exceed approximately  50 mL.  
• Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the samples , as per the Investigator or designee’s discretion. 
7.1.1 Polysomnography  
• Methods: Standard overnight PSG recording and data interpretation will be performed in accordance with the American Academy of Sleep Medicine (AASM) scoring manual. Participant s will be instrumented with standard PSG electrodes. Time of lights out will be 
established according to the participants’ habitual schedule and kept constant across the PSG 
study nights. The participants will be given 8 hours of time- in bed. 
• Scoring: A ll PSG studies (including screening PSG) will be scored by [CONTACT_203785], blinded to treatment assignment. Scoring will be conducted according to the American Academy of Sleep Medicine manual scoring criteria.  
7.2 Safety Assessments  
• Planned time points for all safety assessments are provided in the SoA. 
• Safety monitoring will be guided by [CONTACT_203787], and by [CONTACT_7609] 1 and 2 safety data for the combination. Safety assessments will 
include physical examinations, measurement of vital signs, monitoring and recording of AEs, SAEs, and pregnancies, recording of study or treatment discontinuations. Effects on OSA and sleep parameters (e.g., sleep time and sleep stages) will also be monitored by [CONTACT_63175]. 
• Adverse events of special interest include effects on urine outflow, as both atomoxetine and 
oxybutynin are associated with urinary retention. Effects of atomoxetine on heart rate and 
blood pressure are expected to be modest, as indicated by [CONTACT_203788], and will also be monitored. Participants with serious cardiac abnormalities will be excluded from the study. Suicidal ideation in children and adolescents is a boxed warning for 
atomoxetine; however, analysis in adult patients , the target population for the proposed OSA 
study, did not reveal an increased risk of suicidal ideation or behavior in association with 
atomoxetine. Daytime sleepi[INVESTIGATOR_203766] a potential safety outcome and efficacy outcome in OSA. Both atomoxetine and oxybutynin may be associated with somnolence, and oxybutynin 
is additionally associated with  anticholinergic CNS effects such as memory difficulty.  
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 25 of 50 V2.0 7.2.1 Physical Examinations  
• The general physical examination at s creening includes an assessment of general appearance 
and a review of physical systems (dermatologic, head, eyes, ears, nose, mouth/throat/neck, 
thyroid, lymph nodes, respi[INVESTIGATOR_696], cardiovascular, gastrointestinal, extremities, 
musculoskeletal, neurologic, and psychiatric systems). Height and weight will also be measured and recorded (with shoes removed and wearing light indoor clothing). 
• Investigators should pay special attention to clinical signs related to previous serious 
illnesses.  
7.2.2 Vital Signs  
• Assessment of vital signs (seated blood pressure, pulse rate, body temperature, respi[INVESTIGATOR_862]) will be performed at the time points indicated in the SoA.  
• Vital signs will be measured at all visits in a seated position after [ADDRESS_1119626] and will 
include temperature, respi[INVESTIGATOR_697], systolic and diastolic blood pressure, and pulse. 
Measurements should be made in the same arm of the participant a t each visit.  
• Systolic and diastolic blood pressure will be repeated for a total of [ADDRESS_1119627] 2  minutes apart.  
• The method used to measure body temperature at screening should be maintained throughout 
the study for each participant, and should be indicated (e.g., ear, mouth, armpit). 
7.2.3 Electrocardiograms  
• A [ADDRESS_1119628] 10 minutes.  
7.2.4 Clinical Safety Laboratory Assessments  
• Refer to Section  9.[ADDRESS_1119629] of clinical laboratory tests to be performed and to the SoA for 
the timing and frequency. 
• The Investigator must review the laboratory report and  document this review. The laborat ory 
reports must be filed with the source documents.  
• All protocol- required laboratory assessments  must be conducted in accordance with the 
laboratory manual and the SoA. 
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 26 of 50 V2.0 • If laboratory values from laboratory assessments not specified in the protocol and pe rformed 
at the institution’s local laboratory result in the need for a change in participant management 
or are considered clinically relevant by [CONTACT_737] (e.g., are considered to be an SAE or 
an AE or require dose modification), then the results must be recorded in the e CRF.  
7.3 Adverse Events and Serious Adverse Events  
The definitions of AEs and SAEs can be found in Appendix 3. 
Adverse events will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized representative). 
The Investigator and any qualified designees are responsible for detecting, documenting, and 
reporting events that meet the definition of an AE or SAE and remain responsible for following 
up on AEs that are serious, considered related to the study treatment  or the study, or that caused 
the participant to discontinue the study and/or study treatment . 
7.3.1 Time Period and Frequency for Collecting AE and SAE Information  
All AEs and SAEs will be collected from the time of randomization until the end of the study at 
the time points specified in the SoA. 
All SAEs will be recorded and reported to the Sponsor or designee within 24 hours, as indicated 
in Appendix 3. The Investigator will submit any updated SAE data to the Sponsor within 
24 hours of it being available. 
Investigators are not obligated to actively seek AEs or SAEs after the conclusion of study 
participation. However, if the Investigator learns of any SAE, including a death, at any time after a participant has been discharged  from the study, and he/she considers the event to be reasonably 
related to the study treatment or study participation, the Investigator must promptly notify the 
Sponsor. 
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3. 
7.3.2 Method of Detecting AEs and SAEs 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and non-leading verbal questioning of the participant is the preferred method to inquire about AE occurrence.  
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 27 of 50 V2.0 7.3.3 Follow -up of AEs and SAEs  
After the initial AE/SAE report, the Investigator is required to proactively follow each participant 
at subsequent visits/contacts. All SAEs  will be followed until resolution, stabilization, until the 
event is otherwise explained, or the participant is lost to follow-up. Further information on 
follow-up procedures is given in Appendix 3. 
7.3.4 Regulatory Reporting Requirements for SAE s 
• Prompt notification (within 24 hours, see Appendix 3) by [CONTACT_633490] a study treatment  under clin ical investigation are met.  
• The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study treatment under clinical investigation. The Sponsor will comply with country- specific  regulatory requirements relating to safety 
reporting to the regulatory authority, IRB/Independent Ethics Committees (IEC), and 
Investigators. 
• Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]R) according  to local regulatory requirements and Sponsor policy and 
forwarded to Investigators as necessary. 
• An Investigator who receives an Investigator safety report describing an SAE or other 
specific safety information (e .g., summary or listing of SAE) from the Sponsor will file it 
along with the Investigator’s Brochure and will notify the IRB/IEC, if appropriate according to local requirements.  
7.3.5 Pregnancy  
• Details of all pregnancies in female participants after the start of study treatment and until at least [ADDRESS_1119630] dose will be collected .  
• If a pregnancy is reported, the Investigator should inform the Sponsor within 24 hours of learning of the pregnancy and should follow the procedures outlined in Appendix 4. 
• Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) are considered to be SAEs.  
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND [ADDRESS_1119631] label for advice 
on overdose and: 
1. Contact [CONTACT_27465].  
2. Closely monitor the participant for AE/SAE and laboratory abnormalities until atomoxetine hydrochloride  and/or R-oxybutynin chloride can no longer be detected systemically.  
3. Obtain a plasma sample for P K analysis within [ADDRESS_1119632] dose of study 
treatment  if requested by [CONTACT_1689] (determined on a case by [CONTACT_413]).  
4. Document the quantity of the excess dose as well as the duration of the overdosing in the eCRF.  
Decisions regarding dose interruptions or modifications will be made by [CONTACT_288953]. 
7.[ADDRESS_1119633] 80% power 
to detect a treatment difference at a two -sided 0.[ADDRESS_1119634] -3.7 %min/h. This assumes that the within -subject standard 
deviation is 9, estimated from Study APN -006, and that the discontinuation rate is less than 20%. 
8.2 Populations for Analyses  
For the purposes of analysis, the following analysis sets are defined: 
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 29 of 50 V2.0 Population Description  
Enrolled All participants who signed the ICF (including screening 
failures).  
Modified Intent to Treat (mITT) Population The mITT Population comprises all participants who are randomized , take at least [ADDRESS_1119635] 1 dose of any of the study 
treatments . Participant s will be analyzed for safety based on the 
treatment received  for each period. A precise definition of “as 
actually received” will be added in the Statis tical Analysis Plan 
(SAP).  
Per Protocol (PP) Population The PP Population consists of all participant s without any major 
protocol violations that could influence efficacy assessment. Participant s in this population will be analyzed according to the 
treatment they actually received  for each period . Treatment 
received is defined as the actual treatment taken during each period 
 
8.3 Interim Analyses 
No interim analysis is planned.  
9 Supporting Documentation and Operational Considerations  
9.1 Appendix  1: Regulatory, Ethical, and Study Oversight Considerations  
9.1.1 Regulatory and Ethical Considerations  
• This study will be conducted in accordance with the protocol and with: 
• Consensus ethical principles derived from international guidelines including the 
Declaratio n of Helsinki and Council for International Organizat ions of Medical 
Sciences  International Ethical Guidelines . 
• Applicable International Conference on Harmonisation ( ICH) Good Clinical Practice 
(GCP) Guidelines. 
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 30 of 50 V2.0 • Applicable laws and regulations. 
• The protocol, protocol amendments, ICF, Investigator ’s Brochure, and other relevant 
documents (e.g., advertisements) must be submitted to an IRB/IEC by [CONTACT_125485]/IEC before the study is initiated. 
• Any amendments to the protocol will require IEC/IRB approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study participants. 
• The Investigator will be responsible for the following: 
• Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures established by [CONTACT_1201]/I EC. 
• Notifying the IRB/IEC of SAE or other significant safety findings as required by [CONTACT_1744]/IEC procedures. 
• Overall conduct of the study at the site and adherence to requirements of 21 Code of Federal Regulations ( CFR) , ICH  GCP  guidelines, the IRB/IEC guidelines, European 
regulation 536/2014 for clinical studies (if applicable), and all other applica ble local 
regulations. 
9.1.2 Financial Disclosure  
Investigators and sub-Investigators will provide the S ponsor with sufficient, accurate financial 
information in accordance with local regulations to allow the Sponsor to submit complete and 
accurate financial cer tification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing information on financial interests during the course of 
the study and for 1 year after completion of the study. 
9.1.3 Informed Consent Proc ess 
• The Investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally authorized representative and answer all  questions regarding the 
study. 
• Participants must be informed that their participation is voluntary. Participants will be required to sign a statement of informed consent that meets the requirements of [ADDRESS_1119636]  
requirements, where applicable, and the IRB/IEC or study center. 
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 31 of 50 V2.0 • The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date the written consent was obtained. 
The authorized person obtaining the informed consent must also sign the ICF. 
• Participants must be re -consented to the most current version of the ICF(s) during their 
participation in the study. 
• A copy of the signed ICF(s) must be provided to the participant or the participant’s legally 
authorized representative.  
If a protocol amendment is required, the ICF  may need to be revised to reflect the changes to the 
protocol. If the ICF  is revised, it must be reviewed and approved by [CONTACT_69869]/IRB, 
and signed by [CONTACT_775575]. 
9.1.4 Data Protection  
• Participants will be assigned a unique identifier by [CONTACT_1034]. Any participant records or datasets that are transferred to the Sponsor will contain the identi fier only; participant names 
or any information which would make the participant identi fiable will not be transferred.  
• The participant must be informed that his/her personal study- related data will be used by [CONTACT_19490]. The level of disclosure must also be explained to the participant. 
• The participant must be informed that his/her medical records may be examined by [CONTACT_9325], by 
[CONTACT_6667]/IEC members, and by [CONTACT_6668]. 
9.1.5 Data Quality Assurance  
• All participant data relating to the study will be recorded on printed or e CRF s unless 
transmitted to the Sponsor or designee electronically (e.g., laboratory data). The Investigator 
is responsible for verifying that data entries are accurate and correct by [CONTACT_775578] t he eCRF.  
• The Investigator must maintain accurate documentation (source data) that supports the 
information entered in t he eCRF.  
• The Investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct a ccess to source data documents.  
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 32 of 50 V2.0 • The Sponsor or designee is responsible for the data management of this study including 
quality checking of the data. 
• Study monitors will perform ongoing source data verification to confirm that data entered 
into the eCRF by [CONTACT_1191], complete, and verifiable from source documents; that the safety and rights of participants are being protected; and that the study is 
being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all appl icable regulatory requirements.  
• Records and documents, including signed ICF, pertaining to the conduct of this study must be 
retained by [CONTACT_13177] 5 years after study completion unless local regulations or 
institutional policies require a longer retention period. No records may be destroyed during the retention period without the written approval of the Sponsor. No records may be transferred to another location or party without written notification to the Sponsor. 
• All data generated by [CONTACT_203792]. Data from external sources (such as laboratory data) will be imported into the 
database. Once the eCRF clinical data have been submitted to the central server at the 
independent data center, corrections to the data fie lds will be captured in an audit trail. The 
reason for change, the name [CONTACT_27501], together with the time and date will be logged to provide an audit trail. 
• If additional corrections are needed, the responsible monitor or data manager will raise a 
query in the electronic data capture (EDC) application. The appropriate staff at the study site 
will answer queries sent to the Investigator. The name [CONTACT_203800], and time and date stamp will be captured to provide an audit trail. Once all source data 
verification is complete and all queries are closed, the monitor will lock the database. 
• The specific procedures to be used for data entry and query resolution using the EDC 
system/ eCRF will be provided to study sites in a training manual. In addition, site personnel 
will rece ive training on the EDC system/e CRF.  
9.1.6 Source Documents  
• Source documents provide evidence for the existence of the participant and substantiate the integrity of the data collected. Source documents are filed at the Investigator’s site.  
• Data entered in the eCRF that are transcribed from source documents must be consistent with 
the source documents or the discrepancies must be explained. The Investigator may need to 
request previous medical records or transfer records, depending on the study. Also, current medical records must be available.  
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND [ADDRESS_1119637] been collected and a study site closure visit has been performed. 
The Investigator may initiate study site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination. Reasons for the early closure of a study site by [CONTACT_9330]:  
• Failure  of the Investigator to comply with the protocol, the requirements of the IRB/IEC or 
local health authorities, the Sponsor's procedures, or GCP guidelines. 
• Inadequate recruitment of participants by [CONTACT_108899] . 
• Discontinuation of further study treatment  development. 
9.1.8 Publication Policy  
• The Sponsor will generally support publication of multicenter studies only in their entirety 
and not as individual site dat a.  
• Authorship will be determined by [CONTACT_175067]. 
• The Sponsor retains the right to disapprove any submission for publication, including any publication using trial data, including abstracts, presentations or manuscripts. 
• A summary of the study results will also be posted in a publicly accessible database (e.g., www.ClinTrials.gov).  
 
9.1.9 Protocol Approval and Amendment  
Before the start of the study, the study protocol and/or other relevant documents will be approved 
by [CONTACT_6179]/IRB/Competent Authorities, in accordance with local legal requirements. The 
Sponsor must ensure that all ethical and legal requirements have been met before the first 
participant  is enrolled in the study. 
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND [ADDRESS_1119638] be written, 
receive approval from the appropriate personnel, and receive IRB/IEC/Competent Authority 
approval prior to implementation (if appropriate). Following approval, the protocol 
amendment(s) will be submitted to the US Investigational N ew Drug (IND) under which the 
study is being conducted. 
Administrative changes (not affecting the participant  benefit/risk ratio) may be made without the 
need for a formal amendment. All amendments will be distributed to all protocol recipi[INVESTIGATOR_840], with 
appropriate instructions. 
9.1.[ADDRESS_1119639] 
financial loss due to personal injury caused by [CONTACT_809627]. 
[IP_ADDRESS]  Access to Source Data  
During the study, a monitor will make site visits to review protocol compliance, compare EDC/eCRF entries and individual participant ’s medical records, assess drug accountability, and 
ensure that the study is being conducted according to pertinent regulatory requirements. The 
EDC/eCRF entries will be verified with source documentation. The review of medical records will be performed in a manner to ensure that participant confidentiality is maintained.  
Checking of the EDC/eCRF entries for completeness and clarity, and cross -checking with source 
documents, will be required to monitor the progress of the study. Moreover, regulatory 
authorities of certain countries, IRBs, IECs, and/or the Sponsor’s Clinical Quality Assuran ce 
Group may wish to carry out such source data checks and/or on- site audit inspections. Direct 
access to source data will be required for these inspections and audits; they will be carried out 
giving due consideration to data protection and medical confidentiality. The Investigator assures 
the CRO and the Sponsor of the necessary support at all times. 
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 35 of 50 V2.0 9.2 Appendix  2: Clinical Laboratory Tests  
• The tests detailed in Table 2 will be performed by [CONTACT_2237] . 
• Laboratory testing is performed non-fasting. 
• Additional tests may be performed at any time during the study as determined necessary by 
[CONTACT_9332]. 
Table 2: Protocol- Required Safety Laboratory Assessments  
Laboratory 
Assessments  Parameters  
Hematology  Hematocrit  
Hemoglobin 
Platelet Count  
RBC Count  RBC Indices  ( M C V,  
MCH, MCHC)  
 WBC count with Differential  
 
Serum Chemistry  Albumin  
BUN 
Creatinine  
Potassium 
Sodium  
Bilirubin  
Total Protein  
Uric acid  ALT 
AST  
Alkaline phosphatase 
Calcium  
Glucose  
Total cholesterol  
Chloride 
Bicarbonate  
Routine 
Urinalysis  Specific gravity , bilirubin, color, appearance, leukocyte esterase, nitrite, 
pH, protein (albumin), glucose, ketones, occult blood, urobilinogen 
Microscopic examination ( if positive protein, leukocyte esterase, blood or 
nitrite ) 
Other Tests  • HbA1c ( Screening Visit only)  
• Serum hCG pregnancy test at screening. Additional testing may be performed if needed in WOCBP . 
• Urine test of  drugs of abuse (marijuana, cocaine, amphetamine, 
methamphetamine, opi[INVESTIGATOR_858], phencyclidine)  
Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; BUN = blood urea nitrogen; 
HbA1c = hemoglobin A1c (glycated hemoglobin); hCG = human chorionic gonadotropin; RBC = red blood cell 
count; WBC= white blood cell; WOCBP = women of childbearing potential.  
 
Investigators must document their review of each laboratory safety report. 
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 36 of 50 V2.0 9.3 Appendix  3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting  
Definition of AE  
AE Definition  
• An AE is any untoward medical occurrence in a participant  or clinical study 
participant, temporally associated with the use of a study treatment , whether or not 
considered related to the medicinal product. 
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment . 
 
Events Meeting  the AE Definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments ( e.g., ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the medical and scientific judgment of the Investigator (i .e., not related to progression of 
underlying disease). 
• Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency and/or intensity of the condition. 
• New conditions detected or diagnosed after study treatment  administration even 
though it may have been present before the start of the study. 
• Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction. 
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment  or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdoses should be reported regardless of sequelae. 
• "Lack of efficacy" or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy 
assessments. However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be reported as an AE or SAE if they fulfil l the definition of an 
AE or SAE.  
 
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 37 of 50 V2.0 Events NOT  Meeting the AE Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by [CONTACT_78782]’s condition. 
• The disease/di sorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s condition. 
• Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that leads to the procedure is the AE. 
• Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospi[INVESTIGATOR_307]). 
• Anticipated day -to-day fluctuations of pre-existing disease(s) or condition(s) present 
or detected at the st art of the study that do not worsen. 
 
Definition of SAE  
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met ( e.g., hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death due to 
progression of disease). 
An SAE is defined as any untoward medical occurrence that, at any dose:  
Results in death  
Is life -threatening  
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, 
which hypothetically might have caused death, if it were more severe. 
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 38 of 50 V2.0 Requires inpatient  hospi[INVESTIGATOR_12993], hospi[INVESTIGATOR_809622] (usually 
involving at least an overnight stay) at the hospi[INVESTIGATOR_12332]/or treatment that would not have been appropriate in the physician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_42244]. If a complication prolongs hospi[INVESTIGATOR_9236], the event is serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary, the AE 
should be considered serious. 
Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen from 
baseline is not considered an AE. 
Results in persistent disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  
• This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma ( e.g., sprained ankle) which may interfere wi th or prevent 
everyday life functions but do not constitute a substantial disruption. 
Is a congenital anomaly/birth defect  
Other situations  
• Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately life -threatening or result in death or hospi[INVESTIGATOR_618969]. These events should usually be considered serious. 
Examples of such events include invasive or malignant cancers, intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood dyscrasias, or convulsions 
that do not result in hospi[INVESTIGATOR_059], or development of drug dependency or drug abuse. 
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND [ADDRESS_1119640] ing 
• When an AE/SAE occurs, it is the responsibility of the Investigator to review all 
documentation (e.g., hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) 
related to the event.  
• The Investigator will then record all relevant AE/SAE informatio n in the e CRF.  
• It is not acceptable for the Investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records in lieu of completion of the AE/SAE eCRF page.  
• There may be instances when copi[INVESTIGATOR_809623] . In this case, all participant identifiers, with the exception of 
the participant number, will be blinded on the copi[INVESTIGATOR_809624] . 
• The I nvestigator will attempt to establish a diagnosis of the event base d on signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE.  
Assessment of Intensity  
The I nvestigator will make an assessment of intensity for each AE and SAE reported 
during the study and assign it to one of the following categories: 
• Mild: An event that is easily tolerated by [CONTACT_2299], causing minimal discomfort 
and not interfering with everyday activities. 
• Moderate: An event that causes sufficient disco mfort and interferes with normal 
everyday activities.  
• Severe: An event that prevents normal everyday activities. An AE that is assessed as severe should not be confused with an SAE. Severe is a category utilized for rating 
the intensity of an event; and both AE and SAE can be assessed as severe.  
An event is defined as ‘serious’ when it meets at least one of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.  
 
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 40 of 50 V2.0 Assessment of Causality  
• The I nvestigator is obligated to assess the relationship between study treatment  and 
each occurrence of each AE/SAE.  
• A "reasonable possibility" of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot be 
ruled out. 
• The I nvestigator will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the e vent to study treatment  
administration will be considered and investigated. 
• The I nvestigator will also consult the Investigator’s Brochure and/or Product 
Information, for marketed products, in his/her assessment. 
• For each AE/SAE, the I nvestigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality. 
• There may be situations in which an SAE has occurred and the Investigator has minimal information to include in the initial report to the CRO . However, it is very 
important that the I nvestigator always make an assessment of causality for every 
event before the initial transmission of the SAE data to the CRO . 
• The I nvestigator may change his/her opi[INVESTIGATOR_9242]-up 
information and send an SAE follow-up report with the updated causality assessment. 
• The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.  
 
Follow -up of AE and SAE  
• The I nvestigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_633495]/or causality of the AE or SAE as fully as possible. This may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals. 
• If a participant dies during participation in the study, the Investigator will provide the CRO with a copy of any post-mortem findings including histopathology. 
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 41 of 50 V2.0 • New or updated information will be recorded in the originally completed eCRF.  
• The I nvestigator will submit any updated SAE data to the CRO within 24 hours of 
receipt of the information.  
 
Reporting of SAE to CRO  
SAE Reporting to CRO  
Via EDC Tool 
• The Investigator must report any SAEs to the CRO  within 24 hours of becoming 
aware of the event.  
• When calling to report an SAE, state that you are reporting an SAE and give the 
Investigator’s name, your name, the telephone number where you can be reached, and 
the protocol number and title. 
• The Investigator and the Sponsor (or Sponsor’s designated agent) will review each 
SAE report and the Sponsor/ CRO will evaluate the seriousness and the causal 
relationship of the event to study treatment . In addition, the Sponsor (or Sponsor’s 
designated agent) will evaluate the expectedness according to the reference 
documents (Investigator ’s Brochure or US product labeling for atomoxetine or 
oxybutynin). Based on the Investigator and Sponsor’s assessment of the e vent, a 
decision will be made concerning the need for further action. 
• After the study is completed at a given site, the electronic data collection tool will be 
taken off-line to prevent the entry of new data or changes to existing data. 
• If a site receives a report of a new SAE from a study participant or receives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken off-line, then the site can report this information on a paper SAE form or by [CONTACT_756]. 
• Contacts for SAE reporting can be found in the Study Reference Manual.  
 
All SAEs will be recorded from time of randomization until the end of the study. Serious adverse 
events occurring after the end of the study and coming to the attention of the Investigator must 
be reported only if they are considered (in the opi[INVESTIGATOR_689]) causally- related to 
study treatment.  
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 42 of 50 V2.0  
Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs)  
Any AE that is serious, associated with the use of the study treatment , and unexpected 
(S[LOCATION_003]R) has additional reporting requirements, as described below. 
• If the S[LOCATION_003]R is fatal or life -threatening, associated with study treatment , and 
unexpected, regulatory authorities and IECs will be notified within 7 calendar days 
after th e Sponsor learns of the event. Additional follow -up (cause of death, autopsy 
report, and hospi[INVESTIGATOR_27450]) information should be reported within an additional 8 days 
(15 days total). 
• If the S[LOCATION_003]R is not fatal or life -threatening but is otherwise serious, associated with 
study treatment , and unexpected, regulatory a uthorities and IECs will be notified 
within [ADDRESS_1119641] report any SAEs to the CRO within 24 hours of becoming aware of the 
event. 
When calling to report an SAE, state that you are reporting an SAE and give the Investigator’s 
name, your name, the telephone number where you can be reached, and the protocol number and 
title. 
The Investigator and the Sponsor (or Sponsor’s designate d agent) will review each SAE report 
and the Sponsor/ CRO will evaluate the seriousness and the causal relationship of the event to 
study treatment . In addition, the Sponsor (or Sponsor’s designated agent) will evaluate the 
expectedness according to the reference document s (Investigator ’s Brochure or US product 
labeling for atomoxetine or oxybutynin). Based on the Investigator and Sponsor’s assessment of 
the event, a decision will be made concerning the need for further action. 
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 43 of 50 V2.0 9.4 Appendix  4: Contraceptive Guidance and Collection of Pregnancy 
Information  
Definitions  
WOCBP  
A woman is considered fertile following menarche and until becoming post-menopausal unless 
permanently sterile (see below).  
Women in the following categories are not considered WOCBP: 
1. Premenarchal  
2. Premenopausal female with one of the following: 
• Documented hysterectomy  
• Documented bilateral salpi[INVESTIGATOR_1656]  
• Documented bilateral oophorectomy 
NOTE: Documentation can come from the site personnel’s review of the participant’s medical records, medical examination, or medical history interview.  
3. Post- menopausal female  
• A post-menopausal state is defined as no menses for 12 months without an alternative 
medical cause. A high follicle-stimulating hormone (FSH) level in the post-
menopausal range may be used to confirm a post-menopausal state in women not 
using hormonal contraception or hormonal replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient. 
• Females on HRT  and whose menopausal status is in doubt will be required to use one 
of the non-estrogen hormonal highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post- menopausal status before s tudy enrollment. 
Contraception Guidance:  
Male Participants:  
Male participants with female partners of childbearing potential are eligible to participate if the agree to ONE of the following during the protocol- defined time frame:  
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 44 of 50 V2.0 • Are abstinent from penile-vaginal intercourse as their usual and preferred lifestyle 
(abstinent on a long- term and persistent basis) and agree to remain abstinent.  
• Agree to use a contraceptive method with a fail ure rate of <1% per year as described 
in the table below when having penile-vaginal intercourse with a WOCBP who is not currently pregnant. 
In addition, male participants must refrain from donating sperm for the duration of the study and 
for [ADDRESS_1119642] agree to remain abstinent from 
penile-vaginal intercourse or to use a male condom during each epi[INVESTIGATOR_228058]- defined time frame.  
Female Participants  
Female participants of childbearing potential are eligible to participate if they agree to use a 
highly effective method of contraception consistently and correctly as described in the table below. 
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 45 of 50 V2.0 Highly Effective Contraceptive Methods That Are User Dependent1 
Failure rate of <1% per year when used consistently and correctly. 
Combined (estrogen- and progestin-containing) hormonal contraception associated with 
inhibition of ovulation2 
• Oral 
• Intravaginal 
• Transdermal  
Progestogen -only hormonal contraception associated with inhibition of ovulation  
• Oral 
• Injectable  
Highly Effective Contraceptive Methods That Are User Independent1 
Implantable progestogen-only hormonal contraception associated with inhibition of ovulation 
• IUD 
• Intrauterine hormone- releasing system (IUS)  
• Bilateral tubal occlusion 
Vasectomized partner  
A vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. 
Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment . The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant. 
NOTES:  
1 Typi[INVESTIGATOR_35818]. Use should be consistent with 
local regulations regarding the use of contraceptive methods for participants participating in clinical studies.  
 
 
Pregnancy Testing  
• WOCBP should only be included after a confirmed menstrual period and a negative highly 
sensiti ve serum pregnancy test. 
• An additional serum  pregnancy testing should be performed at Visit 5 (EOS). 
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 46 of 50 V2.0 • Pregnancy testing will be performed whenever a menstrual cycle is missed or when 
pregnancy is otherwise suspected. 
Collection of Pregnancy Information: 
Female participants who become pregnant  
• The Investigator will collect pregnancy information on any female participant who becomes 
pregnant while participating in this study. Information will be recorded on the appropriate 
form and submitted to the Sponsor within 24 hours  of learning of a participant’s pregnancy. 
The participant will be followed to determine the outcome of the pregnancy. The Investigator 
will collect any follow up information on the participant and the neonate and the information will be forwarded to the Sponsor. Generally, follow up will not be required for longer than 6 to 8 weeks beyond the estimated delivery date. Any termination of the pregnancy will be 
reported, regardless of fetal state (presence or absence of anomalies) or indication for the 
procedure. 
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy will be reported as an AE or SAE. A spontaneous 
abortion is always considered to be an SAE and will be reported as such. Any post-study 
pregnancy- related SAE considered re asonably related to the study treatment  by [CONTACT_490836]. While the Investigator is not obligated to 
actively seek this information in former study participants, he or she may learn of an SAE through spontaneous reporting. 
• Any female participant who becomes pregnant while participating in the study will be 
withdrawn from the study. 
  
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 47 of 50 V2.0 9.5 Appendix  5: List of Abbreviations 
AHI apnea -hypopnea index  
AE adverse event  
Bang  Body mass index, Age, Neck circumference, and Gender criteria  
BMI  body mass index 
CFR  Code of Federal Regulations 
CNS  central nervous system  
CPAP  continuous positive air pressure 
CYP2D6  cytochrome P450 2D6  
CYP3A4  cytochrome P450 3A4 
DSM -5 Diagnostic and Statistical Manual of Mental Disorders, 5th edition  
ECG  electrocardiogram  
EEG  electroencephalogram  
eCRF  electronic case report form(s)  
EDC electronic data capture  
EOS  end of study 
FSH follicle -stimulating hormone  
GCP  Good Clinical Practice  
HB Hypoxic burden 
HRT  hormone replacement therapy 
ICF informed consent form 
ICH International Conference on Harmonisation  
IEC Independent Ethics Committee 
IND Investigational New Drug 
IPSS  International Prostate Symptom Score  
IRB Institutional Review Board  
IRT Interactive Response Technology  
OSA obstructive sleep apnea  
OTC  over-the-counter 
MAOI  monoamine oxidase inhibitor 
NREM  non-rapid eye movement  
PK pharmacokinetic(s)  
PSG polysomnography 
QHS  1 dose every night at bedtime  
REM  rapid eye movement 
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND [ADDRESS_1119643]  upper limit of normal  
US [LOCATION_002]  
WOCBP  woman of childbearing potential 
  
  
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND [ADDRESS_1119644]  1997;99:106-109. 
Chan E, Steenland HW, Liu H, Horner RL. Endogenous excitatory drive modulating respi[INVESTIGATOR_203774] -wake states. Am J Respir Crit Care Med 2006;174:1264-1273. 
Eckert DJ, White DP, Jordan AS, Malhotr a A, Wellman A. Defining phenotypic  causes of 
obstructive sleep apnea. Identification of novel therapeutic targets. Am J Respir Crit Care Med  
2013;188:996-1004. 
Findley LJ, Unverzagt ME, Suratt PM. Automobile accidents involving patients  with obstructive 
sleep apnea. Am Rev Respir Dis  1988;138:337-340. 
Hoffstein V . Blood pressure, snoring, obesity, and nocturnal hypoxaemia. Lancet  
1994;344:643-645. Hung J, Whitford EG, Parsons RW, Hillman DR. Association of sleep apnoea with myocardial 
infarction in men. La ncet 1990;336:261-264. 
Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, et al. Association of sleep-
disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart  Health Study. JAMA  2000; 283:1829-1836. 
Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep -
disordered breathing in adults. Am J Epi[INVESTIGATOR_5541] 2013;177(9):1006–1014. 
Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep -
disordered breathing and hypertension. N Engl J Med 2000; 342:1378-1384. 
Redline S, Strauss ME, Adams N, Winters M, Roebuck T, Spry K, et al. Neuropsychological 
function in mild sleep -disordered breathing. Sleep  1997; 20:160-167. 
Shahar E, Whitne y CW, Redline S, Lee ET, Newman AB, Nieto FJ, et al. Sleep -disordered 
breathing and cardiovascular disease: Cross -sectional results of the Sleep Heart Health Study . 
Am J Respir Crit Care Med  2001;163:19-25. 
Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms  in obstructive 
sleep apnea. J Clin Invest  1995;96:1897-1904. 
Weaver TE , Sawyer AM. Adherence to continuous positive airway pressure treatment for
 
obstructive sleep  apnea: implications  for future  interventions. Indian J Med Res 
2010;131:245-258. 
Wellman A, Eckert DJ, Jordan AS, Edwards BA, Passaglia CL, Jackson AC, et al. A method for 
measuring and modeling the physiological traits causing obstructive sleep apnea. J Appl Physiol (1985) 2011; 110:1627-1637. 
Wellman A, Edwards BA, Sands SA, Owens RL, Nemati S, Butler J, et al. A simplified method 
for determining phenotypic traits in patients with obstructive sleep apnea. J Appl Physiol (1985) 
2013;114:911-922. 
Wessendorf TE, Teschler H, Wang YM, Konietzko N, Thilmann AF. Sleep -disordered breathing 
among patients with first- ever stroke. J Neurol  2000;247:41-47. 
Younes M. Contributions of upper airway mechanics and control mechanisms to severity of 
obstructive apnea. Am J Respir Crit Care Med  2003;168:645-658.  
Apnimed, Inc.  Clinical Study Protocol  
Protocol APC -003/IND 141505 CONFIDENTIAL  
 
6 January 2021 50 of 50 V2.0 Declaration of the Investigator 
Title: Phase [ADDRESS_1119645] confidence. This documentation includes this study 
protocol, Investigator's Brochure, EDC system/eCRF, and other scientific data. 
The study will not be commenced without the prior written approval of a properly constituted 
IRB or IEC. No changes will be made to the study protocol without the prior written approval of the Sponsor and the IRB or IEC, except where necessary to eliminate a n immediate hazard to the 
participan ts. 
I have read and understood and agree to abide by [CONTACT_95835]. 
Responsible Investigator of the local study center 
 
_____________________________________ _____________________ 
Signature [CONTACT_1782]  
_____________________________________ 
Name (block letters)  
_____________________________________ 
Title (block letters)  
_____________________________________ Institution (block letters)  
_____________________________________ Phone number 